Zylidac will test whether optogenetic cell lines that hit 21 g/L in small-scale CHO runs can deliver higher-yield complex biologics at GMP scale.
|Articles|August 15, 2014
- BioPharm International-09-15-2014
- Volume 2014 eBook
- Issue 3
Outsourcing Trends in Biopharmaceutical Manufacturing
Author(s)Eric Langer
The author highlights the top 10 outsourcing trends found during a survey of biopharmaceutical manufacturers.
Advertisement
The author highlights the top 10 outsourcing trends found during a survey of biopharmaceutical manufacturers.
Articles in this issue
about 12 years ago
Biopharma Contract Manufacturing Prices Go Up—and Downabout 12 years ago
Ensuring Sound Bioanalytical Methods Transferabout 12 years ago
CMOs Gear Up for Biologics Manufacturing Challengesabout 12 years ago
Weighing Clinical Trial Outsourcing OptionsAdvertisement
Related to this article
Rohit Tripathi, vice president of industry strategy, consumer packaged goods, and manufacturing at RELEX Solutions, explains what is driving biopharma reshoring, how USMCA uncertainty complicates sourcing for biologics, and where cold-chain visibility still breaks down.
Advertisement
Advertisement
Trending on BioPharm International
1
Merck and Kelun’s Sac-TMT Extends Survival by Nearly 7 Months in Pretreated Endometrial Cancer
2
BioNTech’s HER2 ADC Hits Phase 3 Goal, but Companies See Limited Benefit
3
BMS Reports Death in Phase 1 Zolacabtagene Autoleucel MS Study
4
Treasury Proposes Adding Biotech to Outbound Investment Restrictions Under COINS Act
5